Research Open Access
Like 0



Children have a low rate of COVID-19 and secondary severe multisystem inflammatory syndrome (MIS) but present a high prevalence of symptomatic seasonal coronavirus infections.


We tested if prior infections by seasonal coronaviruses (HCoV) NL63, HKU1, 229E or OC43 as assessed by serology, provide cross-protective immunity against SARS-CoV-2 infection.


We set a cross-sectional observational multicentric study in pauci- or asymptomatic children hospitalised in Paris during the first wave for reasons other than COVID (hospitalised children (HOS), n = 739) plus children presenting with MIS (n = 36). SARS-CoV-2 antibodies directed against the nucleoprotein (N) and S1 and S2 domains of the spike (S) proteins were monitored by an in-house luciferase immunoprecipitation system assay. We randomly selected 69 SARS-CoV-2-seropositive patients (including 15 with MIS) and 115 matched SARS-CoV-2-seronegative patients (controls (CTL)). We measured antibodies against SARS-CoV-2 and HCoV as evidence for prior corresponding infections and assessed if SARS-CoV-2 prevalence of infection and levels of antibody responses were shaped by prior seasonal coronavirus infections.


Prevalence of HCoV infections were similar in HOS, MIS and CTL groups. Antibody levels against HCoV were not significantly different in the three groups and were not related to the level of SARS-CoV-2 antibodies in the HOS and MIS groups. SARS-CoV-2 antibody profiles were different between HOS and MIS children.


Prior infection by seasonal coronaviruses, as assessed by serology, does not interfere with SARS-CoV-2 infection and related MIS in children.


Article metrics loading...

Loading full text...

Full text loading...



  1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-44.  https://doi.org/10.1038/s41564-020-0695-z  PMID: 32123347 
  2. Bialek S, Gierke R, Hughes M, McNamara LA, Pilishvili T, Skoff T,, et al. Coronavirus disease 2019 in children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):422-6.  https://doi.org/10.15585/mmwr.mm6914e4  PMID: 32271728 
  3. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 Infection in Children. N Engl J Med. 2020;382(17):1663-5.  https://doi.org/10.1056/NEJMc2005073  PMID: 32187458 
  4. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6):e20200702.  https://doi.org/10.1542/peds.2020-0702  PMID: 32179660 
  5. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42.  https://doi.org/10.1001/jama.2020.2648  PMID: 32091533 
  6. Choi S-H, Kim HW, Kang J-M, Kim DH, Cho EY. Epidemiology and clinical features of coronavirus disease 2019 in children. Clin Exp Pediatr. 2020;63(4):125-32.  https://doi.org/10.3345/cep.2020.00535  PMID: 32252139 
  7. Jones TC, Mühlemann B, Veith T, Biele G, Zuchowski M, Hoffmann J, et al. An analysis of SARS-CoV-2 viral load by patient age; medRxiv. 2020. http://dx.doi.org/2020.06.08.20125484
  8. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.  https://doi.org/10.1056/NEJMoa2002032  PMID: 32109013 
  9. Danis K, Epaulard O, Bénet T, Gaymard A, Campoy S, Botelho-Nevers E, et al. Cluster of coronavirus disease 2019 (COVID-19) in the French Alps, February 2020. Clin Infect Dis. 2020;71(15):825-32.  https://doi.org/10.1093/cid/ciaa424  PMID: 32277759 
  10. Lopez AS, Hill M, Antezano J, Vilven D, Rutner T, Bogdanow L, et al. Transmission dynamics of COVID-19 outbreaks associated with child care facilities - Salt Lake City, Utah, April-July 2020. MMWR Morb Mortal Wkly Rep. 2020;69(37):1319-23.  https://doi.org/10.15585/mmwr.mm6937e3  PMID: 32941418 
  11. Yu C, Zhou M, Liu Y, Guo T, Ou C, Yang L, et al. Characteristics of asymptomatic COVID-19 infection and progression: A multicenter, retrospective study. Virulence. 2020;11(1):1006-14.  https://doi.org/10.1080/21505594.2020.1802194  PMID: 32722990 
  12. Su L, Ma X, Yu H, Zhang Z, Bian P, Han Y, et al. The different clinical characteristics of corona virus disease cases between children and their families in China - the character of children with COVID-19. Emerg Microbes Infect. 2020;9(1):707-13.  https://doi.org/10.1080/22221751.2020.1744483  PMID: 32208917 
  13. Viner RM, Mytton OT, Bonell C, Melendez-Torres GJ, Ward J, Hudson L, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr. 2020. 175(2):143-56.  https://doi.org/10.1001/jamapediatrics.2020.4573  PMID: 32975552 
  14. Sinaei R, Pezeshki S, Parvaresh S, Sinaei R. Why COVID-19 is less frequent and severe in children: a narrative review. World J Pediatr. 2021;17(1):10-20.  https://doi.org/10.1007/s12519-020-00392-y  PMID: 32978651 
  15. Zhou W, Wang W, Wang H, Lu R, Tan W. First infection by all four non-severe acute respiratory syndrome human coronaviruses takes place during childhood. BMC Infect Dis. 2013;13(1):433.  https://doi.org/10.1186/1471-2334-13-433  PMID: 24040960 
  16. K. Ng, N. Faulkner, G. Cornish, A. Rosa, C. Earl, A. Wrobel, et al. Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans; bioRxiv 2020. http://dx.doi.org/2020.05.14.095414
  17. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489-1501.e15.  https://doi.org/10.1016/j.cell.2020.05.015  PMID: 32473127 
  18. J. Braun, L. Loyal, M. Frentsch, D. Wendisch, P. Georg, F. Kurth, et al. Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors; medRxiv 2020. http://dx.doi.org/2020.04.17.20061440
  19. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020;395(10239):1771-8.  https://doi.org/10.1016/S0140-6736(20)31103-X  PMID: 32410760 
  20. Belhadjer Z, Méot M, Bajolle F, Khraiche D, Legendre A, Abakka S, et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. Circulation. 2020;142(5):429-36.  https://doi.org/10.1161/CIRCULATIONAHA.120.048360  PMID: 32418446 
  21. Takada A, Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol. 2003;13(6):387-98.  https://doi.org/10.1002/rmv.405  PMID: 14625886 
  22. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020;395(10237):1607-8.  https://doi.org/10.1016/S0140-6736(20)31094-1  PMID: 32386565 
  23. Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J, Angoulvant F, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. BMJ. 2020;369:m2094.  https://doi.org/10.1136/bmj.m2094  PMID: 32493739 
  24. M. H. Cheng, S. Zhang, R. A. Porritt, M. Arditi, I. Bahar. An insertion unique to SARS-CoV-2 exhibits superantigenic character strengthened by recent mutations; bioRxiv 2020. http://dx.doi.org/2020.05.21.109272
  25. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927-99.  https://doi.org/10.1161/CIR.0000000000000484  PMID: 28356445 
  26. Grzelak L, Temmam S, Planchais C, Demeret C, Tondeur L, Huon C, et al. A comparison of four serological assays for detecting anti-SARS-CoV-2 antibodies in human serum samples from different populations. Sci Transl Med. 2020;12(559):eabc3103.  https://doi.org/10.1126/scitranslmed.abc3103  PMID: 32817357 
  27. R Core Team. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2020. Available from: https://www.R-project.org/
  28. Dijkman R, Jebbink MF, El Idrissi NB, Pyrc K, Müller MA, Kuijpers TW, et al. Human coronavirus NL63 and 229E seroconversion in children. J Clin Microbiol. 2008;46(7):2368-73.  https://doi.org/10.1128/JCM.00533-08  PMID: 18495857 
  29. Garbino J, Crespo S, Aubert J-D, Rochat T, Ninet B, Deffernez C, et al. A prospective hospital-based study of the clinical impact of non-severe acute respiratory syndrome (Non-SARS)-related human coronavirus infection. Clin Infect Dis. 2006;43(8):1009-15.  https://doi.org/10.1086/507898  PMID: 16983613 
  30. Greenberg SB. Update on rhinovirus and coronavirus infections. Semin Respir Crit Care Med. 2011;32(4):433-46.  https://doi.org/10.1055/s-0031-1283283  PMID: 21858748 
  31. Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490-502.  https://doi.org/10.1016/j.tim.2016.03.003  PMID: 27012512 
  32. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020;11(1):4704.  https://doi.org/10.1038/s41467-020-18450-4  PMID: 32943637 
  33. Severance EG, Bossis I, Dickerson FB, Stallings CR, Origoni AE, Sullens A, et al. Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a U.S. metropolitan population. Clin Vaccine Immunol. 2008;15(12):1805-10.  https://doi.org/10.1128/CVI.00124-08  PMID: 18945884 
  34. van der Hoek L, Pyrc K, Berkhout B. Human coronavirus NL63, a new respiratory virus. FEMS Microbiol Rev. 2006;30(5):760-73.  https://doi.org/10.1111/j.1574-6976.2006.00032.x  PMID: 16911043 
  35. S. Khan, R. Nakajima, A. Jain, R. R. de Assis, A. Jasinskas, J. M. Obiero, et al. Analysis of serologic cross-reactivity between common human coronaviruses and SARS-CoV-2 using coronavirus antigen microarray; bioRxiv 2020. http://dx.doi.org/2020.03.24.006544
  36. Y. Peng, A. J. Mentzer, G. Liu, X. Yao, Z. Yin, D. Dong, W., et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients; bioRxiv 2020. http://dx.doi.org/2020.06.05.134551
  37. Esper F, Shapiro ED, Weibel C, Ferguson D, Landry ML, Kahn JS. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis. 2005;191(4):499-502.  https://doi.org/10.1086/428291  PMID: 15655771 
  38. Galipeau Y, Greig M, Liu G, Driedger M, Langlois M-A. Humoral responses and serological assays in SARS-CoV-2 infections. Front Immunol. 2020;11:610688.  https://doi.org/10.3389/fimmu.2020.610688  PMID: 33391281 
  39. Shrock E, Fujimura E, Kula T, Timms RT, Lee I-H, Leng Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science. 2020;370(6520):eabd4250.  https://doi.org/10.1126/science.abd4250  PMID: 32994364 
  40. Toubiana J, Cohen JF, Brice J, Poirault C, Bajolle F, Curtis W, et al. Distinctive features of Kawasaki disease following SARS-CoV-2 infection: a controlled study in Paris, France. J Clin Immunol. 2021;41(3):526-35.  https://doi.org/10.1007/s10875-020-00941-0  PMID: 33394320 

Data & Media loading...

Supplementary data

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error